Updated: Oct 6, 2021
The TGA (Therapeutic Goods Administration) confirmed it would start allowing the sale of low-dose cannabidiol (CBD) products over the counter by pharmacists as of december. Therefore all companies in the space are excited for what’s ahead and could receive a boost in the Australian medical cannabis market.
However the company FreshLeaf declares that the products might not be available until 2022, because they have to prove the quality standard of the products first.
While the companies prepare for the new policy there is still a lot of room to grow for the Australian cannabis market in the near future.
For more informations on hot topics join the Plutux Community and stay up to date!
Disclaimer: eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFD assets. Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money